Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxazosin in Alcoholism
NCT02989493Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Doxazosin with Placebo (2 arms). Primary endpoints: Startle Potentiation During Stress Reactivity Task at 4 weeks and Number of Participants Reporting Any Heavy Drinking Days at 8 weeks. Started Apr 2017; status: completed.
02
Drugs
doxazosin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT02989493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989493.